REGN (Regeneron) Business Value to Revenue

Public company logo of Regeneron (REGN)

Regeneron Pharmaceuticals leverages the success of Dupixent and Eylea while expanding its oncology pipeline and conducting share buybacks. The company generates capital by creating innovative biologics for the therapy of severe allergic and ocular pathologies. This EV/Revenue chart visualizes the enterprise value of the business excluding debt, where 5261.25 reflects the most recent value of the metric. The portfolio of immune system treatments is growing rapidly, providing a unique opportunity for patient recovery.

REGN - Regeneron Corp EV/Sales Multiple over the range 11/23/2025 - 11/20/2026

REGN (Regeneron Inc.): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
- business market valuation indicators:
- money and cash flow information:
Initial company analysis:Regeneron Pharmaceuticals
Mass-produced product of Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals (REGN) possesses a powerful scientific authority in developing breakthrough drugs, allowing the market to price in a high premium to the business value. This indicator compares the total enterprise value with annual revenue, excluding the impact of debt obligations to determine the net market valuation. By analyzing the EV/Sales history, an investor can determine the asset's degree of overbought status and the risks of a correction should financial performance deteriorate.